Kaletra News
CROI: Kivexa and Truvada have similar efficacy and safety - Aidsmap
... when combined with Kaletra, according to a study presented to the recent Fifteenth Conference on Retroviruses and Opportunistic Infections in Boston. ...
CROI: Once daily Kaletra tablets non-inferior to twice daily dose - Aidsmap
Kaletra tablets dosed once daily are no less safe and effective than dosing the drug twice daily, according to a poster presented to the Fifteenth ...
CROI: Atazanavir Equals Lopinavir in Head-On Contest - MedPage Today
Explain to interested patients that both boosted atazanavir (Reyataz) and boosted lopinavir (Kaletra) are approved for treatment of HIV. ...
Report on access to drugs due next week - Bangkok Post
The pressure came after he announced a policy of compulsory licensing (CL) to bypass patents on Aids drugs Efavirenz and Kaletra and the heart drug Plavix. ...
European Advisory Committee Endorses Pediatric Formulation of ... - Kaiser network.org
A European regulatory advisory committee recently recommended approval of a pediatric formulation of Abbott Laboratories' antiretroviral drug Kaletra, ...
Once-daily boosted atazanavir comparable to twice-daily Kaletra in ... - Aidsmap
all 2 news articles
Abbott Laboratories to build nutritionals plant in Singapore - Chicago Tribune
Boost for AIDS pill: In a potential boost to future worldwide sales of Abbott's blockbuster AIDS pill Kaletra, the company says a lower-strength tablet of ...
The Competition Bites Trimeris - Motley Fool
Unfortunately for Trimeris, Fuzeon is only approved as a treatment for patients failing other HIV drugs like Abbott Labs' (NYSE: ABT) Kaletra. ...
Market Report -- In Play (ABT) - MSN Money
Abbott Labs says Kaletra and Aluvia new lower-strength tablet for pediatric use receives positive opinion from EMEA Co announces that the European Committee ...
Kaletra RSS Feed